Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Current Therapeutic Research-clinical and Experimental Pub Date : 2022-01-01 DOI:10.1016/j.curtheres.2022.100674
Benjamin M. Brucker MD , Jennifer King PharmD , Paul N. Mudd Jr PharmD, MBA , Kimberly McHale PhD
{"title":"Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors","authors":"Benjamin M. Brucker MD ,&nbsp;Jennifer King PharmD ,&nbsp;Paul N. Mudd Jr PharmD, MBA ,&nbsp;Kimberly McHale PhD","doi":"10.1016/j.curtheres.2022.100674","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The β<sub>3</sub>-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder. However, β-adrenergic receptors are also found outside the bladder, which could lead to off-target activity.</p></div><div><h3>Objective</h3><p>This study assessed the selectivity of vibegron and mirabegron for β-adrenergic receptors and the maximal effect and potency for β<sub>3</sub>-adrenergic receptors.</p></div><div><h3>Methods</h3><p>Functional cellular assays were performed using Chinese hamster ovary-K1 cells expressing β<sub>1</sub>-, Chinese hamster ovary cells expressing β<sub>2</sub>-, and human embryonic kidney 293 cells expressing β<sub>3</sub>-adrenergic receptors. Cells were incubated with vibegron, mirabegron, or control (β<sub>1</sub> and β<sub>3</sub>, isoproterenol; β<sub>2</sub>, procaterol). Responses were quantified using homogeneous time-resolved fluorescence of cyclic adenosine monophosphate and were normalized to the respective control. Half-maximal effective concentration and maximum response values were determined by nonlinear least-squares regression analysis.</p></div><div><h3>Results</h3><p>Activation of β<sub>3</sub>-adrenergic receptors with vibegron or mirabegron resulted in concentration-dependent β<sub>3</sub>-adrenergic receptor responses. Mean (SEM) half-maximal effective concentration values at β<sub>3</sub>-adrenergic receptors were 2.13 (0.25) nM for vibegron and 10.0 (0.56) nM for mirabegron. At a concentration of 10 µM, β<sub>3</sub>-adrenergic activity relative to isoproterenol was 104% for vibegron and 88% for mirabegron. Maximum response at β<sub>3</sub>-adrenergic receptors was 99.2% for vibegron and 80.4% for mirabegron. β<sub>1</sub>-adrenergic activity was 0% and 3% for vibegron and mirabegron, respectively; β<sub>2</sub>-adrenergic activity was 2% and 15%, respectively.</p></div><div><h3>Conclusions</h3><p>Vibegron showed no measurable β<sub>1</sub> and low β<sub>2</sub> activity compared with mirabegron, which showed low β<sub>1</sub> and some β<sub>2</sub> activity. Both showed considerable selectivity at β<sub>3</sub>-adrenergic receptors; however, vibegron demonstrated near-exclusive β<sub>3</sub> activity and a higher maximum β<sub>3</sub> response.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"96 ","pages":"Article 100674"},"PeriodicalIF":1.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X22000133/pdfft?md5=fc54efeb449cd62aea76d2446cbb04b7&pid=1-s2.0-S0011393X22000133-main.pdf","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X22000133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 20

Abstract

Background

The β3-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder. However, β-adrenergic receptors are also found outside the bladder, which could lead to off-target activity.

Objective

This study assessed the selectivity of vibegron and mirabegron for β-adrenergic receptors and the maximal effect and potency for β3-adrenergic receptors.

Methods

Functional cellular assays were performed using Chinese hamster ovary-K1 cells expressing β1-, Chinese hamster ovary cells expressing β2-, and human embryonic kidney 293 cells expressing β3-adrenergic receptors. Cells were incubated with vibegron, mirabegron, or control (β1 and β3, isoproterenol; β2, procaterol). Responses were quantified using homogeneous time-resolved fluorescence of cyclic adenosine monophosphate and were normalized to the respective control. Half-maximal effective concentration and maximum response values were determined by nonlinear least-squares regression analysis.

Results

Activation of β3-adrenergic receptors with vibegron or mirabegron resulted in concentration-dependent β3-adrenergic receptor responses. Mean (SEM) half-maximal effective concentration values at β3-adrenergic receptors were 2.13 (0.25) nM for vibegron and 10.0 (0.56) nM for mirabegron. At a concentration of 10 µM, β3-adrenergic activity relative to isoproterenol was 104% for vibegron and 88% for mirabegron. Maximum response at β3-adrenergic receptors was 99.2% for vibegron and 80.4% for mirabegron. β1-adrenergic activity was 0% and 3% for vibegron and mirabegron, respectively; β2-adrenergic activity was 2% and 15%, respectively.

Conclusions

Vibegron showed no measurable β1 and low β2 activity compared with mirabegron, which showed low β1 and some β2 activity. Both showed considerable selectivity at β3-adrenergic receptors; however, vibegron demonstrated near-exclusive β3 activity and a higher maximum β3 response.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
维比格仑和米拉比格仑对β3-肾上腺素能受体的选择性和最大反应
β3肾上腺素能激动剂vibegron和mirabegron在治疗膀胱过动症方面已显示出良好的安全性和有效性。然而,膀胱外也发现β-肾上腺素能受体,这可能导致脱靶活动。目的研究维比格仑和米拉比格仑对β-肾上腺素能受体的选择性以及对β-肾上腺素能受体的最大作用和效价。方法用表达β1-的中国仓鼠卵巢- k1细胞、表达β2-的中国仓鼠卵巢细胞和表达β3肾上腺素能受体的人胚胎肾293细胞进行功能细胞检测。细胞用vibegron、mirabegron或对照(β1和β3、异丙肾上腺素;β2,procaterol)。采用单磷酸环腺苷均匀时间分辨荧光定量测定反应,并归一化到相应的对照。采用非线性最小二乘回归分析确定半最大有效浓度和最大响应值。结果vibegron或mirabegron激活β3-肾上腺素能受体导致浓度依赖性β3-肾上腺素能受体反应。β3-肾上腺素能受体的平均(SEM)半最大有效浓度值为:vibegron为2.13 (0.25)nM, mirabegron为10.0 (0.56)nM。在浓度为10µM时,相对于异丙肾上腺素,威比格龙的β3-肾上腺素能活性为104%,米拉比格龙为88%。对β3-肾上腺素能受体的最大反应为vibegron为99.2%,mirabegron为80.4%。威比司隆和米拉比司隆的β1-肾上腺素能活性分别为0%和3%;β2-肾上腺素能活性分别为2%和15%。结论与mirabegron相比,vibegron的β1和β2活性较低,而mirabegron的β1和β2活性较低。两者对β3-肾上腺素能受体均表现出相当的选择性;然而,vibegron显示出几乎完全的β3活性和更高的最大β3反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
31
审稿时长
3 months
期刊介绍: We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.
期刊最新文献
Inhibitory effects of heat-killed lactic acid bacterium Enterococcus faecalis on the growth of Porphyromonas gingivalis Potentially Inappropriate Medications Use and Associated Factors Among Older Patients on Follow-Up at the Chronic Care Clinic of Hiwot Fana Comprehensive Specialized Hospital in Eastern Ethiopia A Narrative Review of the Coronavirus Disease 2019 Response in the Kingdom of Bahrain Effects of Low-Dose Glucagon on Subcutaneous Insulin Absorption in Pigs Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients with Dyslipidemia and Hypertension: A Multicenter Randomized Clinical Trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1